Cumberland Pharmaceuticals (CPIX) Income towards Parent Company (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 16 years of Income towards Parent Company data on file, last reported at -$3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 351.64% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$7.2 million (down 119.88% YoY), and the FY2025 full-year result was -$2.9 million, up 55.75% from the prior year.
• Income towards Parent Company eased to -$3.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $1.2 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
• A 4-year average of -$1.4 million and a median of -$1.4 million in 2025 frame the typical range for Income towards Parent Company.
• Across the five-year window, Income towards Parent Company slumped 1204.25% in 2024 and soared 165.61% in 2025, its largest moves.
• Tracing CPIX's Income towards Parent Company over 4 years: stood at -$6.3 million in 2023, then soared by 69.82% to -$1.9 million in 2024, then rose by 25.57% to -$1.4 million in 2025, then sank by 121.91% to -$3.1 million in 2026.
• Business Quant data shows CPIX's Income towards Parent Company at -$3.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.9 million in Q3 2025.